Un estudio de Fase 1 de seguridad y determinación de dosis de GLIX1 en adultos con glioma de alto grado recurrente o progresivo
Un estudio de fase 1 abierto para evaluar la seguridad y determinar la dosis de GLIX1 administrado por vía oral en adultos con glioma de alto grado recurrente o progresivo
This is an open-label, multicenter dose-escalation study to be followed by a dose expansion to define the optimal dose of GLIX1 as monotherapy by reviewing safety and tolerability, disease characteristics and pharmacokinetic profiles and preliminary clinical activity in participants with a high grade diffuse glioma that progressed during or recurred after prior standard of care therapies or investigational therapies as clinically indicated.
Patients will be treated daily with GLIX1 capsules until disease progression or unacceptable safety.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Glioblastomas (GBMs) are the most common and aggressive primary malignant tumors in adult central nervous system. High-grade glioma almost always recur and/or progress, and upon progression treatment options are very limited with no universal standard therapy established.
GLIX1 is a small molecule administered PO (per os, i.e., orally), that targets the deoxyribonucleic acid (DNA) damage repair mechanism by enhancing Tet methylcytosine dioxygenase 2 (TET2) activity. Increasing the activity of the TET2 enzyme increases DNA oxidation at 5-methylcytosine residues. Such oxidation is normally processed by base excision repair. During base excision repair, a single stranded DNA break is formed. These single strand DNA breaks are well tolerated in normal cells. In cancer, alterations in DNA methylation are common and TET2 activity is inhibited, giving rise to increased DNA methylation in close genomic proximity. When GLIX1 agonizes TET2 activity in cancer cells, excessive base excision repair results in numerous single strand DNA breaks in close proximity, which ultimately converge to form double strand DNA breaks that overwhelm the repair capacity of these cancer cells, resulting in apoptotic cell death.
High-grade glioma have some of the lowest levels of genomic 5-hydroxymethylcytosine. Thus, enhancing the activity of the TET2 enzyme in these cells is likely to have the greatest effect in terms of treating cancers.
Indeed, GLIX1 has been shown to cross the blood brain barrier in rodents and has shown significant activity in various in vitro and in vivo GBM and glioma tumor models.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
California
-
Palo Alto, California, Estados Unidos, 94304
- Reclutamiento
- Stanford University
-
Contacto:
- Lewis Naya
- Número de teléfono: (650) 725-0379
- Correo electrónico: secure-sci-cto-neuro-crcs@lists.stanford.edu
-
-
Florida
-
Tampa, Florida, Estados Unidos, 33612
- Reclutamiento
- Moffitt Cancer Center
-
Investigador principal:
- Patrick Grogan, MD
-
Contacto:
- Patrick Grogan, MD
- Número de teléfono: 813-745-8000
- Correo electrónico: Patrick.grogan@moffitt.org
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60611
- Reclutamiento
- Northwestern Medicine
-
Contacto:
- Ditte Primdahl, MD
- Número de teléfono: 312-695-1202
- Correo electrónico: cancer@northwestern.edu
-
-
New York
-
New York, New York, Estados Unidos, 10016
- Reclutamiento
- NYU Langone Health
-
Investigador principal:
- Alexandra Miller, MD, PhD
-
Contacto:
- Alexandra Miller, MD
- Número de teléfono: (212) 731-6267
- Correo electrónico: cancertrials@nyulangone.org
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Main Inclusion Criteria:
-
Adult patients aged ≥18 years at the time of informed consent
-
Participants must have histologically confirmed Grade 3 or Grade 4 glioma
-
Recurrent or progressive disease
-
A maximum of two prior treatment lines
-
Interval of at least 3 months since the last day off of radiotherapy, unless tumor progression and index lesion is outside the prior radiation field.
-
Interval since last dose of systemic therapy and Baseline MRI of ≥28 days, except:
- for nitrosoureas (e.g., lomustine, carmustine, fotemustine): 42 days (6 weeks)
- for monoclonal antibodies: 42 days (6 weeks)
- for small molecules, 4 weeks or at least 5 half-lives (whatever is longer)
-
Recovered from all toxicities from prior treatments to Grade 1 or less by NCI CTCAE v6.0:
-
Participants receiving corticosteroids must be on a stable or decreasing dose of ≤6 mg daily dexamethasone (or ≤40 mg prednisone) for the 7 days prior to the start of study treatment.
-
Participants with seizures must be adequately controlled on a stable regimen of anti-epileptic drugs.
-
Adequate performance status: Eastern Cooperative Oncology Group (ECOG) 0 or 1.
-
Ability to swallow tablets or capsules.
-
Adequate hematological, liver and renal function.
-
Women of childbearing potential must have a negative serum pregnancy test result within 7 days prior to first dosing. Women must use a highly effective form of contraception (with Pearl Index <1%) for the duration of the study and for at least 3 months after the last dose of study medication.
-
Men with partners of childbearing potential must be willing to use condoms in combination with a second effective method of contraception by the partner during the study and for at least 3 months after the last dose of study medication.
Main Exclusion Criteria:
- Known contraindication for gadolinium (Gd) based, contrast-enhanced MRI
- Prior history of another invasive malignancy unless a complete remission was achieved at least 3 years prior to enrolment AND no additional therapy is required during the study period, except for anti-estrogen or androgen therapy and/or bisphosphonates or denosumab.
- Participants with known active or uncontrolled infection, and/or unexplained fever >38°C in the 3 days prior to the start of study treatment.
- Major non-tumor related surgical procedure or significant traumatic injury within 28 days prior to signing of consent.
- Receiving any investigational products (defined as treatment for which there is currently no regulatory authority-approved indication) within 4 weeks or 5 half-lives (whichever is the longest) prior to Baseline MRI.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación Secuencial
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: GLIX1
Escalating doses of GLIX1, starting at a dose of 1000 mg/day |
Administered orally, once daily, in cycles of 28 days |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Safety Profile of GLIX1 (%Participants with Treatment-emergent Adverse Events)
Periodo de tiempo: From first administration of GLIX1 (Cycle 1 Day 1) until 30 days following last dose administration
|
%Participants with treatment-emergent adverse events (TEAEs) based on CTCAE v6.0 |
From first administration of GLIX1 (Cycle 1 Day 1) until 30 days following last dose administration
|
|
Maximal Tolerated Dose and/or Recommended Dose
Periodo de tiempo: From first administration of GLIX1 (Cycle 1 Day 1) until one cycle of 28 days is complete
|
Maximal Tolerated Dose (MTD) is selected as the dose for which the isotonic estimate of the Dose Limiting Toxicity (DLT) rate is closest to the target rate of 0.3 |
From first administration of GLIX1 (Cycle 1 Day 1) until one cycle of 28 days is complete
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- GLIX1-C101
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .